We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Defects Traced in DiGeorge Syndrome

By Biotechdaily staff writers
Posted on 21 Feb 2003
Researchers have discovered that vascular endothelial growth factor (VEGF) is a modifier of DiGeorge syndrome, which is characterized by the hemizygous deletion of chromosome 22q11 (del22q11). More...
Their findings were reported in the February 2003 issue of Nature Medicine.

DiGeorge syndrome can cause a wide range of heart defects, many of which are vascular in nature, as well as problems with the thymus and parathyroid gland, craniofacial abnormalities, and mental retardation.

The genome of 60-70% of victims of DiGeorge syndrome lacks chromosome 22, which represents a loss of a group of 24 genes. One of these genes, Tbx1, had been considered to be the primary gene involved in DiGeorge syndrome. Researchers from the Medical College of Georgia (Augusta, USA; www.mcg.edu) and Catholic University Leuven (Belgium; www.leuven.ac.be) realized that the wide variety of syndromes presented by sufferers implied the role of other genes, such as that for VEGF.

"It struck us that in the mouse model for DiGeorge syndrome, a lot of the heart defects are vascular in nature, so we looked at one of the major vascular genes, VEGF,” explained senior American investigator Dr. Simon J. Conway, a developmental biologist at the Medical College of Georgia. "If you knock out VEGF from a mouse model, it dies very, very early, before you get a heart, a head, even before you see an embryo proper.”

Working with a VEGF knockout mouse developed by the Belgian group, the investigators found that only the 164/164 form of the VEGF gene was critical to the development of DiGeorge syndrome. Mice lacking this gene developed symptoms similar to DiGeorge syndrome. Dr. Conway explained that something on chromosome 22 was working with VEGF, and that it probably was Tbx1, and that a reduction in Tbx1 and a corresponding reduction in VEGF were enough to produce DiGeorge syndrome.





Related Links:
Medical College of Georgia
Catholic University Leuven

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.